Manage Diarrhea in Patients Receiving Nerlynx® (Neratinib) Tablets

Nerlynx® (neratinib) tablets, an oral kinase inhibitor, is approved by the U.S. Food and Drug Administration for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer, following adjuvant trastuzumab-based therapy.

The recommended dose of neratinib is 240 mg, taken orally as a single dose of six 40 mg tablets, continuously for one year.